ORPHA:99920
Acute graft versus host disease
Query health: suspect — Source fetch failed for trials.
Publications
14,462
Trials
—
Interventional, condition-specific
Researchers
1,619
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0020546
- UMLS:C0856825
- NCIT:C4980
Additional Mondo synonyms (4)
GVHD, acute · acute graft vs. host disease · fulminant graft versus host disease · graft versus host disease, acute
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
14,462 matched papers (8,092 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
6 FDA designations (6 FDA orphan-indication approvals) — e.g. Teduglutide Source
- Interventional trialNot checked
Trial fetch failed or incomplete
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
6
Designations · 6 with FDA orphan-indication approval
- FDA TeduglutideAcute Graft Versus Host Disease · 2020-12-08 · Not FDA Approved for Orphan Indication
- FDA defibrotideAcute Graft Versus Host Disease · 2020-05-14 · Not FDA Approved for Orphan Indication
- FDA itolizumabAcute Graft Versus Host Disease · 2019-02-05 · Not FDA Approved for Orphan Indication
- FDA itolizumabAcute Graft Versus Host Disease · 2019-02-01 · Not FDA Approved for Orphan Indication
- FDA neihulizumabAcute graft-versus-host disease · 2018-01-25 · Not FDA Approved for Orphan Indication
- FDA ex vivo cultured adult human mesenchymal stem cellsAcute Graft Versus Host Disease · 2005-12-14 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
63
Drugs / clinical candidates · MONDO_0020546
- ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)·phase 3
- BASILIXIMAB·phase 3
- BEGELOMAB·phase 3
- BETAMETHASONE·phase 3
- BETAMETHASONE DIPROPIONATE·phase 3
- BETAMETHASONE SODIUM PHOSPHATE·phase 3
- DEXAMETHASONE·phase 3
- ETANERCEPT·phase 3
- METHOTREXATE·phase 3
- METHOXSALEN·phase 3
- METHYLPREDNISOLONE·phase 3
- METHYLPREDNISOLONE ACETATE·phase 3
- PREDNISOLONE·phase 3
- PREDNISONE·phase 3
- REMESTEMCEL-L·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
14,462
14,462 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
14,462 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,092 in the last 10 years · low confidence
Phrase hits: 14,462 · MeSH hits: 0
Who's working on it?
1,619
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y10 papers · 2026
Department of Pediatrics, The Third Clinical Medical College of Inner Mongolia Medical University, Baotou, Inner Mongolia 014010, China.
Papers in Europe PMC - 02Zhang Y10 papers · 2026
Department of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
Papers in Europe PMC - 03Zeiser R9 papers · 2026
Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany.
Papers in Europe PMC - 04Zhang X9 papers · 2026
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Papers in Europe PMC - 05Wang X8 papers · 2026
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
Papers in Europe PMC - 06Chen Y7 papers · 2026
Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.
Papers in Europe PMC - 07Wang L7 papers · 2026
Department of Oncology, Sunshine Union Hospital, Weifang, Shandong, China.
Papers in Europe PMC - 08Wang Y7 papers · 2026
Department of Pediatrics, The Third Clinical Medical College of Inner Mongolia Medical University, Baotou, Inner Mongolia 014010, China.
Papers in Europe PMC - 09
- 10Cao Y6 papers · 2026
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
—
interventional trials for this specific condition
We could not load trial data for this condition right now.
Data as of 11 September 2026
low confidence
Recruiting interventional trials
From the matched ClinicalTrials.gov set
Trial data could not be loaded for this build. This is not the same as finding zero interventional trials.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 141 · after dedupe 136 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 136 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (136)
- ctis·2025-523448-10-00·Authorised·Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
skipped — LLM skipped (--skip-llm)
- ctis·2025-524302-15-00·Authorised·A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
skipped — LLM skipped (--skip-llm)
- ctis·2025-520545-74-00·Authorised, recruiting·Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study.
skipped — LLM skipped (--skip-llm)
- ctis·2025-521093-34-00·Authorised·BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance
skipped — LLM skipped (--skip-llm)
- ctis·2024-510924-38-00·Authorised, recruiting·IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.
skipped — LLM skipped (--skip-llm)
- ctis·2024-514484-25-00·Authorised, ongoing·PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A MYELOABLATIVE REGIMEN BASED ON CYCLOPHOSPHAMIDE AND ETOPOSIDE AS A CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA
skipped — LLM skipped (--skip-llm)
- ctis·2024-514483-11-00·Authorised, ongoing·PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A REDUCED-INTENSITY REGIMEN BASED ON FLUDARABINE AND MELPHALAN AS CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA.
skipped — LLM skipped (--skip-llm)
- ctis·2024-510582-42-02·Cancelled·Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-512657-24-00·Authorised, ongoing·ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia
skipped — LLM skipped (--skip-llm)
- ctis·2024-516599-14-00·Cancelled·Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-515283-31-00·Expired·An open label, multi-center, Phase IV rollover protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with either panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462), and are judged by the investigator to benefit from continued treatment
skipped — LLM skipped (--skip-llm)
- ctis·2024-510590-14-00·Cancelled·Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
skipped — LLM skipped (--skip-llm)
- ctis·2024-516064-28-00·Cancelled·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-513023-17-00·Cancelled·EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
skipped — LLM skipped (--skip-llm)
- ctis·2024-511164-92-00·Cancelled·A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft versus-host disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
skipped — LLM skipped (--skip-llm)
- ctis·2023-507960-38-00·Cancelled·A randomized, single-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy.
skipped — LLM skipped (--skip-llm)
- ctis·2023-505737-26-00·Authorised, ongoing·A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508614-41-00·Authorised, ongoing·A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporeal photopheresis as first-line treatment of Grade II acute graft-versus-host disease with skin involvement occuring after allogeneic stem cell transplantation - COPAVEHDI
skipped — LLM skipped (--skip-llm)
- ctis·2022-502673-41-01·Cancelled·A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
skipped — LLM skipped (--skip-llm)
- ctis·2023-503952-28-00·Expired·A Randomised, Open label, Controlled, Multicentre, Phase 2 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants with Steroid refractory Acute Graft versus host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525933-22-00·Authorised·STRategiEs for Antiplatelet Management foLlowIng acute coroNary syndromE (STREAMLINE)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524977-18-00·Authorised·Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523435-18-00·Authorised·Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524169-26-00·Authorised·An open label multicenter phase II study to investigate the efficacy, safety and
tolerability of the Obe-cel in patients with minimal residual disease (MRD) of
Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL
skipped — LLM skipped (--skip-llm)
- ctis·2026-525740-15-00·Authorised·Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acute graft versus host disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acute graft versus host disease" OR "GVHD, acute" OR "acute graft vs. host disease" OR "fulminant graft versus host disease" OR "graft versus host disease, acute"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
(empty)
Query health: suspect — strategies attempted: phrase; with hits: phrase
Source errors: trials: skipped ClinicalTrials.gov (--skip-trials; typically page-ceiling unmeasurable)
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (14462) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T21:49:13.756Z